These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29504494)

  • 1. A 3-month Safety Assessment of Human Bone Marrow Derived Mesenchymal Stromal Cells Administered Once by the Intramuscular Route to Immunodeficient Mice.
    Creane M; McElroy M; Duffy A; Dawood CS; O'Brien T
    Toxicol Pathol; 2018 Apr; 46(3):290-301. PubMed ID: 29504494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.
    Gupta PK; Krishna M; Chullikana A; Desai S; Murugesan R; Dutta S; Sarkar U; Raju R; Dhar A; Parakh R; Jeyaseelan L; Viswanathan P; Vellotare PK; Seetharam RN; Thej C; Rengasamy M; Balasubramanian S; Majumdar AS
    Stem Cells Transl Med; 2017 Mar; 6(3):689-699. PubMed ID: 28297569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human bone marrow-derived, pooled, allogeneic mesenchymal stromal cells manufactured from multiple donors at different times show comparable biological functions in vitro, and in vivo to repair limb ischemia.
    Thej C; Balasubramanian S; Rengasamy M; Walvekar A; Swamynathan P; Raj SS; Shahani P; Siddikuzzaman ; Kolkundkar U; Seetharam RN; Gupta PK; Majumdar AS
    Stem Cell Res Ther; 2021 May; 12(1):279. PubMed ID: 33971964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
    Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
    J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities.
    Mohamed SA; Howard L; McInerney V; Hayat A; Krawczyk J; Naughton S; Finnerty A; Holohan M; Duffy A; Moloney T; Kavanagh E; Burke P; Liew A; Tubassam M; Walsh SR; O'Brien T
    Cytotherapy; 2020 Jun; 22(6):313-321. PubMed ID: 32273232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice.
    Koch JM; D'Souza SS; Schwahn DJ; Dixon I; Hacker TA
    Cytotherapy; 2016 Feb; 18(2):219-28. PubMed ID: 26740280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials.
    Tappenbeck N; Schröder HM; Niebergall-Roth E; Hassinger F; Dehio U; Dieter K; Kraft K; Kerstan A; Esterlechner J; Frank NY; Scharffetter-Kochanek K; Murphy GF; Orgill DP; Beck J; Frank MH; Ganss C; Kluth MA
    Cytotherapy; 2019 May; 21(5):546-560. PubMed ID: 30878384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).
    Shirbaghaee Z; Heidari Keshel S; Rasouli M; Valizadeh M; Hashemi Nazari SS; Hassani M; Soleimani M
    Stem Cell Res Ther; 2023 Jul; 14(1):174. PubMed ID: 37408043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and biodistribution profile of placental-derived mesenchymal stromal cells (PLX-PAD) following intramuscular delivery.
    Ramot Y; Meiron M; Toren A; Steiner M; Nyska A
    Toxicol Pathol; 2009 Aug; 37(5):606-16. PubMed ID: 19478280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia.
    Bura A; Planat-Benard V; Bourin P; Silvestre JS; Gross F; Grolleau JL; Saint-Lebese B; Peyrafitte JA; Fleury S; Gadelorge M; Taurand M; Dupuis-Coronas S; Leobon B; Casteilla L
    Cytotherapy; 2014 Feb; 16(2):245-57. PubMed ID: 24438903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and retention of locally administered human mesenchymal stromal cells: Quantitative polymerase chain reaction-based detection of human DNA in murine organs.
    Creane M; Howard L; O'Brien T; Coleman CM
    Cytotherapy; 2017 Mar; 19(3):384-394. PubMed ID: 28089755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
    Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
    J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial.
    Mohamed SA; Duffy A; McInerney V; Krawczyk J; Hayat A; Naughton S; Finnerty A; Holohan M; Liew A; Tubassam M; Walsh SR; O'Brien T; Howard L
    Cytotherapy; 2022 Dec; 24(12):1259-1267. PubMed ID: 35999133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
    Nakamizo A; Marini F; Amano T; Khan A; Studeny M; Gumin J; Chen J; Hentschel S; Vecil G; Dembinski J; Andreeff M; Lang FF
    Cancer Res; 2005 Apr; 65(8):3307-18. PubMed ID: 15833864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of angiogenic effects by hypoxia-preconditioned human umbilical cord-derived mesenchymal stem cells in a mouse model of hindlimb ischemia.
    Han KH; Kim AK; Kim MH; Kim DH; Go HN; Kim DI
    Cell Biol Int; 2016 Jan; 40(1):27-35. PubMed ID: 26222206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans.
    Ra JC; Shin IS; Kim SH; Kang SK; Kang BC; Lee HY; Kim YJ; Jo JY; Yoon EJ; Choi HJ; Kwon E
    Stem Cells Dev; 2011 Aug; 20(8):1297-308. PubMed ID: 21303266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice.
    Cruz FF; Borg ZD; Goodwin M; Sokocevic D; Wagner D; McKenna DH; Rocco PR; Weiss DJ
    Stem Cells Transl Med; 2015 Jun; 4(6):615-24. PubMed ID: 25925837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Therapeutic Efficacy and Reducing Cell Dosage in Stem Cell Transplantation Therapy for Ischemic Limb Diseases by Modifying the Cell Injection Site.
    Shin JY; Yoon JK; Noh MK; Bhang SH; Kim BS
    Tissue Eng Part A; 2016 Feb; 22(3-4):349-62. PubMed ID: 26824782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease.
    Kim KW; Moon SJ; Park MJ; Kim BM; Kim EK; Lee SH; Lee EJ; Chung BH; Yang CW; Cho ML
    Stem Cell Res Ther; 2015 Oct; 6():202. PubMed ID: 26497134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxic mesenchymal stem cells engraft and ameliorate limb ischaemia in allogeneic recipients.
    Huang WH; Chen HL; Huang PH; Yew TL; Lin MW; Lin SJ; Hung SC
    Cardiovasc Res; 2014 Feb; 101(2):266-76. PubMed ID: 24220639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.